Tiziana Life Sciences Ltd (NasdaqCM: TLSA)
Health Care · Biotechnology · GB
$1.09
-8.40% today · -44.1% 1Y
Tiziana Life Sciences Ltd (NasdaqCM: TLSA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $153.88M and employs 10 people.
Over the last twelve months the share price has lost 44.1%, trading between 0.76 and 2.25.
Tweenvest scores Tiziana Life Sciences Ltd across four factors: quality 25/100, value 68/100. Its strongest factor is value.
TLSA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $153.88M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.16
- Dividend yield
- —
- Beta (5Y)
- 0.44
- 52-week high
- $2.25
- 52-week low
- $0.76
- Avg volume (3M)
- —
- Shares outstanding
- 129.31M
- Employees
- 10
- Next earnings
- —
About Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.
- ISIN
- BMG889121031
- Listed since
- Nov 20, 2018
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| BNC KOREA, Inc.KOSDAQ: A256840 | $155.68M | ₩3,060.00 | -3.01% |
| Helixmith Co., LtdKOSDAQ: A084990 | $155.16M | ₩4,530.00 | +22.60% |
| Innovacell Inc.TSE: 504A | $155.13M | ¥544.00 | -9.63% |
| Mycenax Biotech Inc.TPEX: 4726 | $154.11M | NT$23.80 | +2.59% |
| NovaBridge BiosciencesNasdaqGM: NBP | $153.12M | $1.32 | -5.38% |
| BioInvent International AB (publ)OM: BINV | $152.68M | Skr23.10 | -0.43% |
| Minerva Neurosciences, Inc.NasdaqCM: NERV | $151.84M | $2.89 | -9.12% |
| Essex Bio-Technology LimitedSEHK: 1061 | $149.73M | HK$2.08 | -3.26% |
Figures last refreshed Oct 11, 2026.